Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSTC100 SAD and MAD Study in Healthy Adult Subjects
NCT07752472Phase 1Recruiting
- Sponsor
- Prospect Therapeutics
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PSTC100 in metabolic disorder (4 arms), sponsored by Prospect Therapeutics. Primary endpoints: Time to Peak Concentration, Peak Concentration and 16 more. Started Sep 2026; status: recruiting.
02
Drugs
PSTC100
03
Conditions
metabolic disorder
Beyond the preview
Go deeper on NCT07752472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752472.